Effect of Neoadjuvant Chemoradiation and Surgical Technique on Recurrence of Localized Pancreatic Cancer

Journal of Gastrointestinal Surgery

Volumn 16, Issue 1, 2012, Pages 68-79

  Katz, Matthew H G ^a   Wang, Huamin ^a   Balachandran, Aparna ^a   Bhosale, Priya ^a   Crane, Christopher H ^a   Wang, Xuemei ^a   Pisters, Peter W T ^a   Lee, Jeffrey E ^a   Vauthey, Jean Nicolas ^a   Abdalla, Eddie K ^a   Wolff, Robert ^a   Abbruzzese, James ^a   Varadhachary, Gauri ^a   Chopin Laly, Xavier ^a   Charnsangavej, Chusilp ^a   Fleming, Jason B ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Chemoradiation; Mesopancreas; Pancreatic cancer; Pancreaticoduodenectomy; SMA margin; Surgery

Indexed keywords

ANTINEOPLASTIC AGENT; CAPECITABINE; DEOXYCYTIDINE; DRUG DERIVATIVE; FLUOROURACIL; GEMCITABINE;

ADENOCARCINOMA; ADJUVANT CHEMORADIOTHERAPY; ADJUVANT THERAPY; ADULT; AGED; ARTICLE; BLEEDING; COMPUTER ASSISTED TOMOGRAPHY; DISEASE FREE SURVIVAL; DISSECTION; FEMALE; HUMAN; KAPLAN MEIER METHOD; LYMPH NODE METASTASIS; MALE; METHODOLOGY; MIDDLE AGED; MULTIVARIATE ANALYSIS; PANCREAS TUMOR; PANCREATICODUODENECTOMY; PATHOLOGY; PROPORTIONAL HAZARDS MODEL; RADIATION DOSE FRACTIONATION; RADIOGRAPHY; RETROSPECTIVE STUDY; SUPERIOR MESENTERIC ARTERY; TUMOR RECURRENCE;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; BLOOD LOSS, SURGICAL; CHEMORADIOTHERAPY, ADJUVANT; DEOXYCYTIDINE; DISEASE-FREE SURVIVAL; DISSECTION; DOSE FRACTIONATION; FEMALE; FLUOROURACIL; HUMANS; KAPLAN-MEIER ESTIMATE; LYMPHATIC METASTASIS; MALE; MESENTERIC ARTERY, SUPERIOR; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOADJUVANT THERAPY; NEOPLASM RECURRENCE, LOCAL; PANCREATIC NEOPLASMS; PANCREATICODUODENECTOMY; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; TOMOGRAPHY, X-RAY COMPUTED; YOUNG ADULT;

EID: 84855344030     PISSN: 1091255X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11605-011-1748-7     Document Type: Article

References (37)

1. Iacobuzio-Donahue CA, Fu B, Yachida S et al. DPC4 gene status of the primary carcinoma correlates with patterns of failure in patients with pancreatic cancer. Journal of clinical oncology: Official Journal of the American Society of Clinical Oncology 2009; 27: 1806-1813.
2. Sebag-Montefiore D, Stephens RJ, Steele R et al. Preoperative radiotherapy versus selective postoperative chemoradiotherapy in patients with rectal cancer (MRC CR07 and NCIC-CTG C016): a multicentre, randomised trial. Lancet 2009; 373: 811-820.
3. Heald RJ, Ryall RD. Recurrence and survival after total mesorectal excision for rectal cancer. Lancet 1986; 1: 1479-1482.
4. Quirke P, Steele R, Monson J et al. Effect of the plane of surgery achieved on local recurrence in patients with operable rectal cancer: a prospective study using data from the MRC CR07 and NCIC-CTG CO16 randomised clinical trial. Lancet 2009; 373: 821-828.
5. Silberfein EJ, Kattepogu KM, Hu CY et al. Long-term survival and recurrence outcomes following surgery for distal rectal cancer. Ann Surg Oncol 2010; 17: 2863-2869.
6. Hernandez JM, Morton CA, Al-Saadi S et al. The natural history of resected pancreatic cancer without adjuvant chemotherapy. The American surgeon 2010; 76: 480-485.
7. Sperti C, Pasquali C, Piccoli A, Pedrazzoli S. Recurrence after resection for ductal adenocarcinoma of the pancreas. World journal of surgery 1997; 21: 195-200.
8. Oettle H, Post S, Neuhaus P et al. Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial. JAMA: the journal of the American Medical Association 2007; 297: 267-277.
9. Klinkenbijl JH, Jeekel J, Sahmoud T, et al. Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region: phase III trial of the EORTC gastrointestinal tract cancer cooperative group. Annals of Surgery 1999; 230: 776-782; discussion 782-774.
10. Katz MH, Merchant NB, Brower S et al. Standardization of surgical and pathologic variables is needed in multicenter trials of adjuvant therapy for pancreatic cancer: results from the ACOSOG Z5031 trial. Ann Surg Oncol 2011; 18: 337-344.
11. Evans DB, Rich TA, Byrd DR et al. Preoperative chemoradiation and pancreaticoduodenectomy for adenocarcinoma of the pancreas. Arch Surg 1992; 127: 1335-1339.
12. Evans DB, Varadhachary GR, Crane CH et al. Preoperative gemcitabine-based chemoradiation for patients with resectable adenocarcinoma of the pancreatic head. J Clin Oncol 2008; 26(21): 3496-3502.
13. Katz MH, Pisters PW, Evans DB, et al. Borderline resectable pancreatic cancer: the importance of this emerging stage of disease. J Am Coll Surg 2008; 206: 833-846; discussion 846-838.
14. Pisters PW, Abbruzzese JL, Janjan NA et al. Rapid-fractionation preoperative chemoradiation, pancreaticoduodenectomy, and intraoperative radiation therapy for resectable pancreatic adenocarcinoma. J Clin Oncol 1998; 16: 3843-3850.
15. Varadhachary GR, Wolff RA, Crane CH et al. Preoperative gemcitabine and cisplatin followed by gemcitabine-based chemoradiation for resectable adenocarcinoma of the pancreatic head. J Clin Oncol 2008; 26(21): 3487-3495.
16. Gaedcke J, Gunawan B, Grade M et al. The mesopancreas is the primary site for R1 resection in pancreatic head cancer: relevance for clinical trials. Langenbeck's archives of surgery / Deutsche Gesellschaft fur Chirurgie 2010; 395: 451-458.
17. Raut CP, Tseng JF, Sun CC et al. Impact of resection status on pattern of failure and survival after pancreaticoduodenectomy for pancreatic adenocarcinoma. Annals of surgery 2007; 246: 52-60.
18. Katz MH, Wang H, Fleming JB et al. Long-term survival after multidisciplinary management of resected pancreatic adenocarcinoma. Ann Surg Oncol 2009; 16: 836-847.
19. Gerard JP, Azria D, Gourgou-Bourgade S et al. Comparison of two neoadjuvant chemoradiotherapy regimens for locally advanced rectal cancer: results of the phase III trial ACCORD 12/0405-Prodige 2. Journal of clinical oncology: official journal of the American Society of Clinical Oncology 2010; 28: 1638-1644.
20. Hwang RF, Wang H, Lara A et al. Development of an integrated biospecimen bank and multidisciplinary clinical database for pancreatic cancer. Ann Surg Oncol 2008; 15: 1356-1366.
21. Katz MH, Hwang R, Fleming JB, Evans DB. Tumor-node-metastasis staging of pancreatic adenocarcinoma. CA Cancer J Clin 2008; 58: 111-125.
22. Varadhachary GR, Tamm EP, Abbruzzese JL et al. Borderline resectable pancreatic cancer: definitions, management, and role of preoperative therapy. Ann Surg Oncol 2006; 13: 1035-1046.
23. Aloia TA, Lee JE, Vauthey JN et al. Delayed recovery after pancreaticoduodenectomy: a major factor impairing the delivery of adjuvant therapy? J Am Coll Surg 2007; 204: 347-355.
24. Yen TW, Abdalla EK, Pisters PW, Evans DB. Pancreaticoduodenectomy. In Von Hoff DD, Evans DB, Hruban RH (eds): Pancreatic cancer. Sudbury: Jones and Bartlett 2005; 265-286.
25. Exocrine pancreas. In Edge SB, Byrd DR, Compton CC et al. (eds): AJCC Cancer Staging Manual, 7th Edition. Chicago: Springer 2009; pp 241-249.
26. Exocrine pancreas. In Greene FL, Page DL, Fleming ID et al. (eds): AJCC Cancer Staging Manual, 6th Edition. Chicago: Springer 2002; 157-164.
27. Tseng JF, Raut CP, Lee JE, et al. Pancreaticoduodenectomy with vascular resection: margin status and survival duration. Journal of Gastrointestinal Surgery: Official Journal of the Society for Surgery of the Alimentary Tract 2004; 8: 935-949; discussion 949-950.
28. Lin LI. A concordance correlation coefficient to evaluate reproducibility. Biometrics 1989; 45: 255-268.
29. Chao YK, Yeh CJ, Chang HK et al. Impact of circumferential resection margin distance on locoregional recurrence and survival after chemoradiotherapy in esophageal squamous cell carcinoma. Ann Surg Oncol 2011; 18: 529-534.
30. Wibe A, Rendedal PR, Svensson E et al. Prognostic significance of the circumferential resection margin following total mesorectal excision for rectal cancer. The British journal of surgery 2002; 89: 327-334.
31. Gockel I, Domeyer M, Wolloscheck T et al. Resection of the mesopancreas (RMP): a new surgical classification of a known anatomical space. World journal of surgical oncology 2007; 5: 44.
32. Winter JM, Cameron JL, Campbell KA, et al. 1423 pancreaticoduodenectomies for pancreatic cancer: A single-institution experience. Journal of Gastrointestinal Surgery: Official Journal of the society for Surgery of the Alimentary Tract 2006; 10: 1199-1210; discussion 1210-1191.
33. Neoptolemos JP, Stocken DD, Dunn JA et al. Influence of resection margins on survival for patients with pancreatic cancer treated by adjuvant chemoradiation and/or chemotherapy in the ESPAC-1 randomized controlled trial. Annals of surgery 2001; 234: 758-768.
34. Baque P, Iannelli A, Delotte J et al. Division of the right posterior attachments of the head of the pancreas with a linear stapler during pancreaticoduodenectomy: vascular and oncological considerations based on an anatomical cadaver-based study. Surgical and radiologic anatomy: SRA 2009; 31: 13-17.
35. van den Broeck A, Sergeant G, Ectors N et al. Patterns of recurrence after curative resection of pancreatic ductal adenocarcinoma. European journal of surgical oncology: the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology 2009; 35: 600-604.
36. Pancreas (exocrine). In Pathologists CoA (ed) College of American Pathologists Cancer Protocols. 2009.
37. Verbeke CS, Menon KV. Variability in reporting resection margin status in pancreatic cancer. Annals of surgery 2008; 247: 716-717.